Kraj: Kanada
Język: angielski
Źródło: Health Canada
RISEDRONATE SODIUM; CALCIUM (CALCIUM CARBONATE); VITAMIN D3
WARNER CHILCOTT CANADA CO
M05BB04
RISEDRONIC ACID, CALCIUM AND CHOLECALCIFEROL, SEQUENTIAL
35MG; 1000MG; 880UNIT
GRANULES (EFFERVESCENTS)
RISEDRONATE SODIUM 35MG; CALCIUM (CALCIUM CARBONATE) 1000MG; VITAMIN D3 880UNIT
ORAL
100
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0351668001; AHFS:
CANCELLED PRE MARKET
2018-02-16
_ _ _ _ PRODUCT MONOGRAPH Pr ACTONEL SACHET KIT TM Risedronate Sodium (as the hemi-pentahydrate) 35 mg Tablets Professed Standard Bone Metabolism Regulator Plus Calcium Carbonate 2500 mg and Vitamin D 3 880 IU Effervescent Granules for Oral Solution Professed Standard Vitamin and Mineral Supplement ATC: M05BA07 Warner Chilcott Canada Co. PO Box 4367, Station A Toronto, ON M5W 3N7 Marketed with sanofi-aventis Canada Inc. Laval, QC H7L 4A8 Date of Preparation: February 16, 2010 Submission Control No: 136548 2 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ............................................................................3 INDICATIONS AND CLINICAL USE ..................................................................................3 CONTRAINDICATIONS........................................................................................................4 WARNINGS AND PRECAUTIONS ......................................................................................4 ADVERSE REACTIONS........................................................................................................6 DRUG INTERACTIONS ........................................................................................................9 DOSAGE AND ADMINISTRATION ..................................................................................12 OVERDOSAGE.....................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY.................................................................14 STORAGE AND STABILITY ..............................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING..................................................19 PART II: SCIENTIFIC INFORMATION ...............................................................................20 PHARMACEUTICAL INFORMATION.................... Przeczytaj cały dokument